Xiaoli Wang, PhD
About Me
Dr. Wang completed her bachelor, master degrees in China in 1994 and 1998, respectively. She received her Ph.D. in Radiology at Jilin University, China in 2001. Dr. Wang did her post-doctoral training in Pathology/Hematology at Kansai Medical University, Japan. Currently, she is faculty member of Division of Hematology/Medical Oncology, Department of Medicine at Icahn School of Medicine at Mount Sinai. Dr. Wang has been Co-Investigator on NIH-funded research projects within the MPN Research Consortium, Principle Investigator on MPN Research Foundation and industry sponsored preclinical studies. She is conducting research independently and within the MPN Research Consortiums. Her research efforts have been focused on understanding normal and malignant hematopoietic stem cell biology and pre-clinical evaluation of effectiveness of small molecule inhibitors as well as immunotherapeutic approaches in eliminating malignant stem cells of patients with MPNs and patients with MPN-Blast Phase (MPN-BP). Dr. Wang’s research has been published in 27 highly ranked peer-reviewed journals including J Clin Invest and Blood and her expertise has been recognized by multiple collaborators.
Language
Position
Research Topics
Cancer, Cell Biology, Cell Transformation, Hematopoiesis, Stem Cells, Translational Research
About Me
Dr. Wang completed her bachelor, master degrees in China in 1994 and 1998, respectively. She received her Ph.D. in Radiology at Jilin University, China in 2001. Dr. Wang did her post-doctoral training in Pathology/Hematology at Kansai Medical University, Japan. Currently, she is faculty member of Division of Hematology/Medical Oncology, Department of Medicine at Icahn School of Medicine at Mount Sinai. Dr. Wang has been Co-Investigator on NIH-funded research projects within the MPN Research Consortium, Principle Investigator on MPN Research Foundation and industry sponsored preclinical studies. She is conducting research independently and within the MPN Research Consortiums. Her research efforts have been focused on understanding normal and malignant hematopoietic stem cell biology and pre-clinical evaluation of effectiveness of small molecule inhibitors as well as immunotherapeutic approaches in eliminating malignant stem cells of patients with MPNs and patients with MPN-Blast Phase (MPN-BP). Dr. Wang’s research has been published in 27 highly ranked peer-reviewed journals including J Clin Invest and Blood and her expertise has been recognized by multiple collaborators.
Language
Position
Research Topics
Cancer, Cell Biology, Cell Transformation, Hematopoiesis, Stem Cells, Translational Research
